Aggrenox and Doxycycline drug interactions - from FDA reports

Summary

Drug interactions are reported among people who take Aggrenox and Doxycycline together. This study is created by eHealthMe based on reports of 23 people who take Aggrenox and Doxycycline from FDA, and is updated regularly.



What's eHealthMe?

eHealthMe is a health data analysis company based in Mountain View, California. eHealthMe monitors and analyzes the outcomes of drugs and supplements that are currently on the market. The results are readily available to health care professionals and consumers.

eHealthMe has released original studies on market drugs and worked with leading universities and institutions such as IBM, London Health Science Centre, Mayo Clinic, Northwestern University and VA. eHealthMe studies have now been referenced in over 500 peer-reviewed medical publications.

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference.

The information that eHealthMe collects includes:

  • Side effects (including severity and how people recover from them)
  • Associated conditions or symptoms
  • Drug effectiveness
  • Demographic data regarding drug use

How the study uses the data?

The study is based on aspirin; dipyridamole and doxycycline hyclate (the active ingredients of Aggrenox and Doxycycline, respectively), and Aggrenox and Doxycycline (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

What is Aggrenox?

Aggrenox has active ingredients of aspirin; dipyridamole. It is often used in stroke. (latest outcomes from Aggrenox 6,384 users)

What is Doxycycline?

Doxycycline has active ingredients of doxycycline hyclate. It is often used in acne. (latest outcomes from Doxycycline 33,323 users)

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.


On Mar, 19, 2019

23 people who take Aggrenox, Doxycycline are studied.


Number of reports submitted per year:

Aggrenox and Doxycycline drug interactions.

Most common drug interactions over time *:

< 1 month:
  1. Confusional state
  2. Diarrhoea
  3. Fatigue (feeling of tiredness)
  4. Febrile neutropenia (fever with reduced white blood cells)
  5. Glomerulonephritis membranous (nephritis with inflammation of the capillary loops in the renal glomeruli)
  6. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  7. Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream)
1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:
  1. Nephrogenic anaemia (anaemia due to kidney disease)
  2. Renal failure (kidney dysfunction)
  3. Chronic kidney disease
10+ years:
  1. Autonomic failure syndrome (a degenerative disease of the autonomic nervous system)
  2. Back pain
  3. Cervical radiculopathy (disturbance of nerve function that causes pain in the upper body)
  4. Diarrhoea
  5. Glaucoma (increased fluid pressure in the eye with vision loss)
  6. Intervertebral disc degeneration (spinal disc degeneration)
  7. Rash
  8. Somnolence (a state of near-sleep, a strong desire for sleep)
  9. Spinal column stenosis (narrowing of spinal column)
not specified:
  1. Tardive dyskinesia (a disorder that involves involuntary movements)
  2. Tooth fracture
  3. Back pain
  4. Rash
  5. Somnolence (a state of near-sleep, a strong desire for sleep)
  6. Abdominal pain upper
  7. Actinomyces test positive
  8. Acute myocardial infarction (acute heart attack)
  9. Anaemia (lack of blood)
  10. Anaphylactic reaction (serious allergic reaction)

Most common drug interactions by gender *:

female:
  1. Tardive dyskinesia (a disorder that involves involuntary movements)
  2. Abdominal pain upper
  3. Acute myocardial infarction (acute heart attack)
  4. Anaemia (lack of blood)
  5. Ankle fracture
  6. Anxiety
  7. Arterial occlusive disease (slow process through which arteries throughout the body become progressively narrowed and eventually completely blocked)
  8. Arthralgia (joint pain)
  9. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  10. Atrioventricular block first degree (heart block first degree)
male:
  1. Anxiety
  2. Arteriosclerosis (thickening and hardening of arteries)
  3. Atrial flutter (an abnormal heart rhythm that occurs in the atria of the heart)
  4. Atrioventricular block first degree (heart block first degree)
  5. Cataract (clouding of the lens inside the eye)
  6. Cerebral atrophy (decrement in size of brain)
  7. Decreased interest
  8. Dizziness
  9. Dyspnoea exertional (breathlessness or shortness of breath)
  10. Faecal incontinence (a lack of control over passing stool)

Most common drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:
  1. Intervertebral disc herniation (spinal disc herniation)
  2. Nausea (feeling of having an urge to vomit)
  3. Vomiting
50-59:
  1. Actinomyces test positive
  2. Anaemia (lack of blood)
  3. Anaphylactic reaction (serious allergic reaction)
  4. Arteriosclerosis (thickening and hardening of arteries)
  5. Arthralgia (joint pain)
  6. Ataxia (loss of full control of bodily movements)
  7. Atelectasis (partial or complete collapse of the lung)
  8. Back pain
  9. Balanitis candida (inflammation of the glands penis by infection with candida albicans)
  10. Bladder dilatation
60+:
  1. Atrioventricular block first degree (heart block first degree)
  2. Confusional state
  3. Arteriosclerosis (thickening and hardening of arteries)
  4. Asthenia (weakness)
  5. Atelectasis (partial or complete collapse of the lung)
  6. Atrial flutter (an abnormal heart rhythm that occurs in the atria of the heart)
  7. Cataract (clouding of the lens inside the eye)
  8. Cerebral atrophy (decrement in size of brain)
  9. Cerebral infarction (less blood supply to brain resulting tissue damage)
  10. Decreased interest

* Approximation only. Some reports may have incomplete information.


Do you take Aggrenox and Doxycycline?

You are not alone:




Related studies

Browse interactions by gender and age

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+


Interactions between Aggrenox and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Interactions between Doxycycline and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Browse all drug interactions of Aggrenox and Doxycycline
a b c d e f g h i j k l m n o p q r s t u v w x y z

What would happen?

Predict new side effects and undetected conditions when you take Aggrenox and Doxycycline (1,025 reports studied)



FDA reports used in this study


Recent updates

Recent general studies
Recent personal studies


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.